Clinical Trial Update: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A randomized Phase II study evaluated axitinib as a monotherapy or in combination with lomustine for recurrent glioblastoma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CeeNU (lomustine)
• INLYTA (AXITINIB)

Snippet

Sponsor: Bart Neyns | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED